Dipna Pharmachem Limited has fulfilled its quarterly regulatory obligations by submitting a compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The submission, made on April 15, 2026, addresses the company's dematerialization activities during Q4FY26.

Regulatory Compliance Details

The certificate was submitted in accordance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation mandates listed companies to provide quarterly confirmations regarding their dematerialization processes through their designated Registrar and Share Transfer Agents.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate confirming specific operational details for the quarter. The RTA confirmed that no securities were received from depository participants for dematerialization during the period from December 31, 2025 to March 31, 2026.

The certificate further states that since no securities were processed for dematerialization, no physical certificates required mutilation and cancellation. Consequently, there was no need for substitution of depository names in the register of members as registered owners within the stipulated 15-day timeframe.

Corporate Governance

The submission was authorized by Keyur Dipakkumar Shah, Managing Director of Dipna Pharmachem Limited, bearing DIN 03167258. The document was digitally signed and submitted to BSE Limited, demonstrating the company's commitment to maintaining transparent corporate governance practices.

Company Information

Dipna Pharmachem Limited operates under CIN L24100GJ2011PLC066400 with its registered office located in Ahmedabad, Gujarat. The company maintains its regulatory compliance through systematic quarterly reporting to stock exchanges and regulatory authorities.

Dipna Pharmachem Limited has issued a clarification to BSE Limited regarding significant movement in its share price, stating that no material information from the company caused the volatility.

Company Response to BSE Inquiry

In a letter dated April 7, 2026, Dipna Pharmachem Limited responded to BSE's inquiry about significant price movement in the company's scrip. The company clarified that it has no price-sensitive or material information that could result in or has resulted in significant movement in its share price.

Regulatory Compliance Status

The pharmaceutical company confirmed that it has made all necessary disclosures under the applicable regulations of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. These disclosures were made within the stipulated time period as per regulations and may have a possible impact or cause fluctuation on the company's share price.

Market Movement Attribution

Dipna Pharmachem Limited emphasized that there is currently no event, information, or announcement that needs to be reported to the stock exchange. The company attributed the volatility in its share price to natural market forces rather than any company-specific developments.

The response was signed by Keyur Dipakkumar Shah, Managing Director (DIN: 03167258), and submitted to BSE Limited's Phiroze Jeejeebhoy Tower office in Mumbai. The company requested BSE to take the clarification on record.